Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Pharmacol Ther ; 101(5): 675-683, 2017 May.
Article in English | MEDLINE | ID: mdl-28032893

ABSTRACT

Achieving therapeutic anticoagulation efficiently with warfarin is important to reduce thrombotic and bleeding risks and is influenced by genotype. Utilizing data from a diverse population of 257 patients who received VKORC1 and CYP2C9 genotype-guided warfarin dosing, we aimed to examine genotype-associated differences in anticoagulation endpoints and derive a novel pharmacogenetic nomogram to more optimally dose warfarin. We observed significant differences across patients with 0, 1, or ≥2 reduced-function VKORC1 or CYP2C9 alleles, respectively, in time to achieve therapeutic international normalized ratio (INR) (7.8 ± 5.8, 7.2 ± 4.7, and 5.4 ± 4.6 days, P = 0.0004) and mean percentage of time in therapeutic range in the first 28 days (22.2, 27.8, and 32.2%, P = 0.0127) with use of existing pharmacogenetic algorithms. These data suggest that more aggressive dosing is necessary for patients with 0 to 1 VKORC1/CYP2C9 variants to more efficiently achieve therapeutic anticoagulation. Herein, we provide a novel kinetic/pharmacodynamic-derived dosing nomogram optimized for a heterogeneous patient population.


Subject(s)
Anticoagulants/administration & dosage , Pharmacogenetics , Warfarin/administration & dosage , Algorithms , Alleles , Anticoagulants/pharmacokinetics , Anticoagulants/therapeutic use , Cytochrome P-450 CYP2C9/genetics , Dose-Response Relationship, Drug , Endpoint Determination , Female , Genotype , Humans , Male , Middle Aged , Vitamin K Epoxide Reductases/genetics , Warfarin/pharmacokinetics , Warfarin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...